$辉瑞(PFE)$ Pfizer (PFE) and Valneva (VALN) said Monday that their investigational vaccine candidate LB6V against outdoor Lyme disease reduced the rate of confirmed cases by 73.2% compared with placebo in a phase 3 clinical study.
$辉瑞(PFE)$ Pfizer (PFE) and Valneva (VALN) said Monday that their investigational vaccine candidate LB6V against outdoor Lyme disease reduced the rate of confirmed cases by 73.2% compared with placebo in a phase 3 clinical study.
Comments